UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Modeling tumor size dynamics based on real‐world electronic health records and image data in advanced melanoma patients receiving immunotherapy

CPT: pharmacometrics and systems pharmacology, 2023-08, Vol.12 (8), p.1170-1181

2023

Volltextzugriff (PDF)

Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management

Current neurology and neuroscience reports, 2018-01, Vol.18 (1), p.3-9, Article 3

2018

Volltextzugriff (PDF)

Physical approaches to treat glioblastoma

Current opinion in oncology, 2020-11, Vol.32 (6), p.640-649

2020

Volltextzugriff (PDF)

Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis

Neurology : neuroimmunology & neuroinflammation, 2018-03, Vol.5 (2), p.e439-e439

2018

Volltextzugriff (PDF)

NIMG-34. THE IMPACT OF TUMOR TREATING FIELDS (TTFIELDS) ON BRAIN ANATOMY USING COMPUTATIONAL ANATOMY ANALYSIS

Neuro-oncology (Charlottesville, Va.), 2018-11, Vol.20 (suppl_6), p.vi183-vi183

2018

Volltextzugriff (PDF)

Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging

JCO clinical cancer informatics, 2023-05, Vol.7 (7), p.e2200126

2023

Volltextzugriff (PDF)

Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2033-2033

2016

Volltextzugriff (PDF)

Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14123-e14123

2016

Volltextzugriff (PDF)

Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study

International journal of laboratory hematology, 2016-02, Vol.38 (1), p.42-49

2016

Volltextzugriff (PDF)

Efficacy, Tolerance and Safety of New Intragastric Air-Filled Balloon (Heliosphere BAG) for Obesity: the Experience of 17 Cases

Obesity surgery, 2010-09, Vol.20 (9), p.1227-1230

2010

Volltextzugriff (PDF)

Evolution of transmitted HIV‐1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

HIV medicine, 2018-10, Vol.19 (9), p.619-628

2018

Volltextzugriff (PDF)

Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

Clinical microbiology and infection, 2019-11, Vol.25 (11), p.1443-1446

2019

Volltextzugriff (PDF)

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study

Open forum infectious diseases, 2018-06, Vol.5 (6), p.ofy113-ofy113

2018

Volltextzugriff (PDF)

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

Clinical microbiology and infection, 2012-08, Vol.18 (8), p.E299-E304

2012

Volltextzugriff (PDF)

THU-133-Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience

Journal of hepatology, 2019-04, Vol.70 (1), p.e218-e219

2019

Volltextzugriff (PDF)

The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy

Journal of medical virology, 2014-10, Vol.86 (10), p.1648-1655

2014

Volltextzugriff (PDF)

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort

Journal of antimicrobial chemotherapy, 2013-01, Vol.68 (1), p.200-205

2013

Volltextzugriff (PDF)

Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting

Journal of antimicrobial chemotherapy, 2009-09, Vol.64 (3), p.616-624

2009

Volltextzugriff (PDF)

Low rate of virological failure and maintenance of susceptibility to HIV‐1 protease inhibitors with first‐line lopinavir/ritonavir‐based antiretroviral treatment in clinical practice

Journal of medical virology, 2010-12, Vol.82 (12), p.1996-2003

2010

Volltextzugriff (PDF)

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

Journal of medical virology, 2011-03, Vol.83 (3), p.391-398

2011

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(18)

Publikationsform

Artikel
(20)

Sprache

Englisch
(20)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Modeling tumor size dynamics based on real‐world electronic health records and image data in advanced melanoma patients receiving immunotherapy

Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management

Physical approaches to treat glioblastoma

Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis

NIMG-34. THE IMPACT OF TUMOR TREATING FIELDS (TTFIELDS) ON BRAIN ANATOMY USING COMPUTATIONAL ANATOMY ANALYSIS

Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging

Phase I/II study of S49076, a multi-target inhibitor of c-MET, AXL, FGFR in combination with bevacizumab in patients with recurrent glioblastoma

Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB)

Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study

Efficacy, Tolerance and Safety of New Intragastric Air-Filled Balloon (Heliosphere BAG) for Obesity: the Experience of 17 Cases

Evolution of transmitted HIV‐1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016

Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study

Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010

THU-133-Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience

The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy

Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort

Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting

Low rate of virological failure and maintenance of susceptibility to HIV‐1 protease inhibitors with first‐line lopinavir/ritonavir‐based antiretroviral treatment in clinical practice

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

Aktive Filter

Suchergebnisse filtern